Tilray Brands, Inc.

TLRY ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-121.4M $-2.19B $-245.0M $-1.45B $-476.8M $-367.4M $-271.1M $-321.2M
Depreciation & Amortization $154.6M $67.8M $18.7M $15.8M
Depreciation $12.5M $9.3M
Amortization $27.3M $11.0M $9.8M
Stock-Based Compensation $45.9M $24.3M $31.8M $39.6M $36.0M $17.4M $29.7M $31.8M
Net Cash from Operating Activities $-69.1M $-94.6M $-30.9M $7.9M $-177.3M $-44.7M $-129.4M $-258.1M
Investing Activities
Capital Expenditures $32.9M $29.2M $20.8M $34.1M $38.9M $44.6M $73.7M
Business Acquisitions $53.7M $18.1M $60.6M $26.7M $-326.0K $-66.6M $25.9M $163.9M
Net Cash from Investing Activities $-55.8M $-46.7M $128.3M $-285.1M $-21.5M $46.1M $-41.7M $-253.2M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $131.0M $133.5M $-75.2M $70.2M $128.2M $124.3M $264.8M $114.7M
Net Change in Cash $7.7M $-6.7M $21.7M $-209.3M $-72.6M $127.8M $92.9M $-390.5M
Free Cash Flow $-127.5M $-60.2M $-12.9M $-211.3M $-83.6M $-174.0M $-331.8M
← Newer Page 1 of 2 Older →